Felicitex Therapeutics Inc.

Felicitex is a biotechnology company based in Natick, MA, focused on developing innovative treatments for dormant cancers by targeting mechanisms of cancer survival and acquired resistance. Their approach involves depriving cancer cells of their dormant state, making them vulnerable to therapies and enhancing treatment efficacy.

The company currently has three clinical drug candidates prepared for Investigational New Drug (IND) enabling studies, showcasing their commitment to advancing cancer treatment options. By addressing the unique challenges of cancer resistance, metastasis, and recurrence, Felicitex aims to improve outcomes for patients facing these complex conditions.

Generated from the website